Svejgaard EL, Brandrup F, Kragballe K, Larsen PO, Veien NK, Holst M, Andersen BL, Bro-Jørgensen AV, Dahl JC, Frentz G, Graudal C, Kamp P, Kroman N, Larsen FS, Mikkelsen F, Munkvad JM, Olafsson JH, Rothenborg H, Staberg B, Søndergaard J, Thulin H.
DOI: 10.2340/0001555555776669

The treatment of onychomycosis has previously often been protracted and unsuccessful. Terbinafine has been shown to be effective in short-term regimens. In this double-blind, placebo-controlled study, 148 patients with toenail dermatophytosis were randomized to treatment with either 250 mg terbinafine daily or placebo for 3 months. An additional treatment was given for 3 months to patients whose infection had not responded. The patients were followed clinically and mycologically through 12 months. After 3 months 82% of the terbinafine-treated group, versus 5% of the placebo group, showed significant improvement, i.e. negative culture and growth of unaffected nail more than 2 mm (p = < 0.0001). After 12 months clinical and mycological cure was seen in 40% of the patients treated with terbinafine for 3 or 6 months, while 67-81% were clinically cured, but with positive microscopy. Side-effects occurred in 13.5% of the terbinafine group, versus 5.4% of the placebo group, and were mild. 250 mg terbinafine daily for 3 months was significantly more effective than placebo. The efficacy did not appear to improve with additional treatment for 3 months.